Strange that the first significant clinical study with NMN is published and no-one posts about it.
Looks like 250 Mg a day for 10 weeks resulted in significant increase in muscle insulin sensitivity.
https://science.scie...ce.abe9985.full
These results demonstrate NMN increases muscle insulin sensitivity, insulin signaling and remodeling in women with prediabetes who are overweight or obese
I guess NR fans don’t bring this up because NR was unsuccessful in addressing Insulin resistance even when given at 2 grams a day for 12 weeks in the Dollarup study, as well as in 2 others.
https://pubmed.ncbi....h.gov/29992272/
12 wk of NR supplementation in doses of 2000 mg/d appears safe, but does not improve insulin sensitivity and whole-body glucose metabolism
https://pubmed.ncbi....h.gov/31412242/
NR supplementation of 1000 mg/d for 6 wk in healthy overweight or obese men and women increased skeletal muscle NAD+ metabolites, affected skeletal muscle acetylcarnitine metabolism, and induced minor changes in body composition and sleeping metabolic rate. However, no other metabolic health effects were observed.
However, no effects of NR were found on insulin sensitivity, mitochondrial function, hepatic and intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, ambulatory blood pressure, plasma markers of inflammation, or energy metabolism.
https://pubmed.ncbi....h.gov/32320006/
However, no effects of NR were found on insulin sensitivity, mitochondrial function, hepatic and intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, ambulatory blood pressure, plasma markers of inflammation, or energy metabolism.
To be fair, Dr. Brenner points out his objection to this study on twitter:
https://twitter.com/...434248753029121
the placebo group's fatty liver started with > 2.3 x the fatty liver as the NMN group. this was significant with a P value of 0.003, which was greater than any NMN-dependent effect in the paper…I would LOVE for NMN and NR to do what these authors say it does in prediabetic women but the baseline characteristics of study participants don't permit one to make such conclusions. you can't compare women w/o fatty liver to those w fatty liver and call it a fair trial
Edited by able, 24 April 2021 - 07:05 PM.